Fevarin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fevarin

What is Fevarin?

Fevarin is a medication that belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRIs). It contains the active substance fluvoxamine maleate. This medication is primarily used to treat certain mental health conditions by acting on the chemical messengers within the brain.

Mechanism of Action

The brain contains various naturally occurring chemicals, including serotonin, which help regulate mood, sleep, and behavior. In individuals experiencing certain psychological conditions, the balance of serotonin may be altered.

Fevarin works by increasing the availability of serotonin in the space between nerve cells in the brain. It achieves this by inhibiting the reabsorption (reuptake) of serotonin into the nerve cells. By maintaining higher levels of serotonin, the medication helps to improve the transmission of nerve impulses, which can assist in stabilizing mood and reducing symptoms associated with specific mental health disorders.

Therapeutic Use

Fevarin is typically utilized for the management of the following conditions:

  • Depressive Illness: It is used to treat major depressive episodes, helping to alleviate symptoms such as persistent sadness, loss of interest, and low energy.
  • Obsessive-Compulsive Disorder (OCD): It is indicated for the treatment of symptoms of OCD, which involve recurrent, unwanted thoughts (obsessions) and repetitive behaviors (compulsions) that a person feels driven to perform.

Because it targets specific pathways in the brain, Fevarin is considered a selective treatment, meaning it has a primary focus on the serotonin system rather than affecting multiple neurotransmitter systems simultaneously.

Regulatory References

  1. NIH MedlinePlus on Fluvoxamine
  2. NIH LiverTox on Fluvoxamine

What side effects are possible with Fevarin?

Possible Side Effects and Safety Information

The safety profile of Fevarin (Fluvoxamine maleate) is characterized by specific adverse reactions classified by frequency and involvement of bodily systems, as defined in official regulatory documents such as the FDA and EMA labeling. The most frequently documented adverse reaction is nausea, which is classified as very common (affecting more than 1 in 10 patients) and often tends to lessen after some days of treatment.

Documented Adverse Reactions

Side effects categorized as common (affecting up to 1 in 10 patients) include effects on the Nervous System (e.g., headache, somnolence, insomnia, tremor, dizziness) and Gastrointestinal Disorders (e.g., dry mouth, constipation, diarrhea, vomiting). Other common effects involve the Psychiatric system (anxiety, nervousness) and General Disorders (asthenia, sweating). Effects on the Reproductive System include sexual dysfunction.

Serious Safety Considerations

The official labeling highlights the potential for several serious adverse reactions. The risk of Suicidal ideation and behavior requires close monitoring, particularly at the beginning of treatment or following dose changes, especially in young adults and pediatric patients. A potentially life-threatening condition known as Serotonin Syndrome is documented, with increased risk when Fevarin is co-administered with other serotonergic agents, such as Monoamine Oxidase Inhibitors (MAOIs), which is a contraindication. Other serious, but rare adverse events include convulsions (seizures) and clinically significant conditions like Hyponatremia (low sodium levels in the blood).

Population-Specific Safety Notes

Safety constraints noted in regulatory documents include the need for careful use in older adults, who may be at a higher risk of Hyponatremia. Caution is also advised for patients with existing Hepatic or Renal Impairment, and those with a history of unstable epilepsy.

Overdose and Emergency Response

Fevarin Overdose and When to Seek Help

The information below summarizes the official, documented risks and required actions in case of an overdose involving Fevarin (fluvoxamine maleate), based on governmental regulatory sources.

Documented Overdose Symptoms

Symptoms reported in cases of acute overdose commonly include somnolence (drowsiness), nausea, vomiting, diarrhoea, dizziness, and tachycardia (fast heart rate). More serious manifestations have included convulsions (seizures), coma, and other cardiac complications or hepatic function abnormalities. Overdose may also be associated with serotonin syndrome.

Emergency Actions and Risks

Immediate medical help is required in all cases of suspected overdose. Contact a Poison Control Center or seek urgent medical care right away. There is no specific antidote for fluvoxamine overdose. Treatment is primarily symptomatic and supportive. Medical procedures, such as gastric lavage followed by the administration of activated charcoal, may be considered by medical professionals to limit absorption.

Overdose involving fluvoxamine alone is rarely associated with death. However, the risk of serious complications and fatality is significantly increased in cases of mixed overdose—when Fevarin is ingested in combination with other substances, including alcohol or other medicines.

Therapeutic Uses of Fevarin

Fevarin (Fluvoxamine maleate) is a medication used to address the core symptoms of Obsessive-Compulsive Disorder (OCD), a therapeutic area associated with this medication, which involves disruptive recurrent, unwanted thoughts (obsessions) and ritualized, repetitive behaviors (compulsions). The medication is relevant in clinical settings marked by heightened patient distress from severe anxiety disorders, specifically Social Anxiety Disorder.

It is commonly used to help manage symptom clusters that may become intense or disruptive, including those associated with Major Depressive Disorder, Panic Disorder, and conditions within the obsessive-compulsive spectrum such as Bulimia Nervosa. The primary benefit is supportive: Fevarin helps to ease the emotional responses and discomfort, helping patients cope more steadily with difficult episodes.

“The primary goal of Fevarin is to provide symptomatic relief and may assist with maintaining functional stability when symptoms interfere with routine activities.”

Mitigation of Intense Symptoms

Fevarin is applied across domains where additional symptomatic support is needed, often used during phases when symptoms become more noticeable and create noticeable interference with daily functioning. It helps address patterns of intense fear of being scrutinized and resulting avoidance behaviors. By easing the overall symptom load, the medication contributes to easing the overall symptom load during symptomatic phases.

Quick Fact: Relevant for Managing Compulsive and Avoidant Behaviors

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Fevarin (Fluvoxamine) eligibility is strictly determined by regulatory authorities based on concurrent medications, age, and specific health conditions.

Populations for Whom Use is Contraindicated

Use is absolutely prohibited for patients with:

  • Known Hypersensitivity to fluvoxamine maleate or any excipients.
  • Concomitant use of Monoamine Oxidase Inhibitors (MAOIs), tizanidine, pimozide, alosetron, or ramelteon.

Age-Related Eligibility Rules

  • Adults (18+): Standard use is established for approved indications.
  • Pediatric Patients (8–17 years): Use is established and approved only for Obsessive-Compulsive Disorder (OCD); use for other conditions is not recommended. Safety and efficacy have not been established for children under 8 years of age.
  • Older Adults (Geriatric): Use requires caution and careful monitoring due to decreased drug clearance and increased risk of low sodium levels (hyponatremia).

Condition-Specific Restrictions

  • Organ Impairment: Patients with hepatic or renal insufficiency should be started on a low dose and carefully monitored.
  • Epilepsy: Fevarin must be avoided in patients with unstable epilepsy; patients with controlled epilepsy require careful monitoring.
  • Pregnancy and Lactation: Use during pregnancy is permitted only if the potential benefit outweighs the risk to the fetus. Use during lactation is generally not recommended or contraindicated as the drug is secreted in human breast milk.

What should I know about interactions with other medicines?

The official regulatory profile for Fevarin (Fluvoxamine maleate) is defined by two principal interaction patterns: pharmacokinetic enzyme inhibition and pharmacodynamic augmentation, which dictate specific restrictions.

Contraindicated Combinations and Restrictions

Co-administration is strictly prohibited with several substances, including Monoamine Oxidase Inhibitors (MAOIs), Tizanidine, Pimozide, Thioridazine, Alosetron, and Ramelteon. The use of MAOIs requires a mandatory separation period (washout) before starting Fevarin. Patients are also advised to avoid alcohol and serotonergic products like St. John's Wort and Tryptophan due to documented interaction risks.

Pharmacokinetic Interactions

Fevarin is officially classified as a potent inhibitor of multiple Cytochrome P450 (CYP) enzymes, notably CYP1A2 and CYP2C19. This pharmacokinetic interaction significantly reduces the clearance of co-administered drugs that are metabolized by these enzymes. This leads to an officially documented increase in the plasma concentration of substances such as Theophylline, Warfarin, Clozapine, and certain Beta-blockers, requiring regulatory caution. For patients with hepatic impairment, a decrease in the drug’s own clearance is documented, increasing the potential for interaction severity.

Pharmacodynamic Interactions

Co-administration with other serotonergic agents, including Triptans, Tramadol, and Lithium, carries a documented risk of Serotonin Syndrome due to additive effects. Furthermore, combining Fevarin with drugs affecting hemostasis, such as NSAIDs and Aspirin, is associated with an increased regulatory risk of Abnormal Bleeding.

Mechanism of Action

Fevarin's mechanism of action is defined by a dual-pathway profile operating at the synaptic and cellular levels to establish regulated neurochemical communication.

Selective Enhancement of Serotonergic Tone

The primary mechanism involves the selective inhibition of the serotonin transporter (SERT), a protein responsible for 5-HT reuptake into the presynaptic neuron. Blocking this reuptake immediately increases the concentration and duration of Serotonin ( 5-HT) in the synaptic space, leading to a long-term amplification of serotonergic signaling across the central nervous system. This sustained signal initiates the cascade of systemic adaptation—including the desensitization of inhibitory 5- HT1 A autoreceptors—necessary for the establishment of regulated neurochemical communication.

Modulation of Neuronal Cellular Resilience

Fevarin possesses a unique secondary mechanism through its agonism at the Sigma-1 receptor (sigma1), a molecular chaperone located on the endoplasmic reticulum of neurons. This activation modulates cellular stress responses and regulates internal processes like Ca^2+ homeostasis and neuroplasticity. This domain is crucial as it complements the primary SERT blockade by modulating the structural integrity and adaptability of the targeted neural tissues, promoting the long-term physiological changes required for regulated neural communication.

Causal Time Lag and Systemic Adaptation

Although the molecular interaction ( SERT blockade) is immediate, the full physiological effect is subject to a physiological time lag. The establishment of regulated neurochemical communication relies on the subsequent homeostatic adjustment of the neural circuits, which takes weeks to fully manifest. This mechanistic limitation explains why the eventual physiological effect is a process of systemic adaptation rather than an immediate chemical event.

Dosage and Administration Information

Fevarin (Fluvoxamine maleate) is a medication for oral administration only, available as immediate-release tablets (25 mg, 50 mg, 100 mg) and extended-release capsules (100 mg, 150 mg). The standard initiation of therapy involves a low starting dose, typically 50 mg/day for the immediate-release form, which is intended to be slowly titrated (increased) in 50 mg increments at weekly or sub-weekly intervals up to the maximum recommended daily intake of 300 mg.

The dosing schedule requires careful attention to the total daily amount. Doses up to 100 mg are typically taken once daily at bedtime. However, when the prescribed daily dose exceeds 100 mg (or 150 mg in certain regions), the total amount should be divided and administered in two or three separate doses, with the largest portion given at bedtime. Fevarin can be taken with or without food.

Administration involves ensuring that tablets and capsules are swallowed whole with water; the extended-release capsule must not be crushed, broken, or chewed to ensure the integrity of the slow-release delivery. For special populations, such as older adults and individuals with hepatic impairment, instructions indicate starting with a low dose and proceeding with slow titration. If a dose is missed, the guidance indicates it should be taken when remembered, unless it is almost time for the next scheduled dose, in which case the missed dose is skipped to prevent doubling the intake. Finally, the entire course of treatment requires gradual dose reduction (tapering) when discontinuing, as abrupt cessation is discouraged.

Recent Clinical Evidence

Research evidence / Overview of studies for Fevarin

Evidence for Use in Obsessive-Compulsive Disorder (OCD)

Research examining the clinical profile of Fevarin in Obsessive-Compulsive Disorder (OCD) includes short-term randomized controlled trials (RCTs), systematic reviews, and continuation studies. These studies were conducted for the clinical situation of OCD in adults, with outcomes monitored using recognized scales, such as the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Across multiple systematic reviews, research compared the measurements of symptom severity when Fevarin was studied against a placebo in short-term research scenarios. Other trials examined changes in symptom intensity when studied alongside other pharmacological agents. Research also explored the use of Fevarin in specific pediatric populations, including children and adolescents with OCD; however, findings were reported to show differences in measurement patterns compared to those observed in adult populations.


Evidence for Use in Social Anxiety Disorder (SAD)

Research for Fevarin in Social Anxiety Disorder (SAD) involved placebo-controlled RCTs that explored fluctuating or unstable symptoms of fear and avoidance. These studies mainly included adult populations, and research examined patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning, such as the Sheehan Disability Scale (SDS). Studies conducted during periods of increased symptom activity examined differences in measured changes in social anxiety symptom severity when compared to placebo measurements. Research also explored intermediate continuation studies, where observation periods of up to 24 weeks were used in research exploring short-term symptom changes.


Research Gaps and Areas of Uncertainty

While a substantial body of evidence describes the research base for Fevarin's main indications, regulatory assessments and systematic reviews note areas requiring further data. Follow-up durations for long-term data were not extensive in the initial regulatory evidence base, indicating that long-term effects are not fully established across all studied conditions. Furthermore, evidence quality varies across studies, and the overall data on measured outcomes in comparison to placebo has been discussed in scientific literature. Research does not determine whether an individual will respond similarly to the group patterns described in the studies.

Key Studies & References

  1. Fluvoxamine vs placebo for outpatients with symptomatic COVID-19, a fully remote randomized - Digital Commons@Becker
  2. ANNEX I SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARIES OF PRODUCT CHARACTERISTICS PRESENTED BY THE EMEA (Fluvoxamine)

Frequently Asked Questions (FAQ)

Common questions about Fevarin (FAQ)

Q: How long does it typically take for a person to notice the effects of Fevarin?

A: Clinical studies have shown efficacy over a period of several weeks, with trials for Obsessive-Compulsive Disorder (OCD) lasting up to 13 weeks. As with most medications of this type, the full therapeutic effect is typically not immediate and requires time for the body to make the necessary neurochemical adjustments. Official information indicates that a period of weeks is often required before the intended effects manifest.

Q: Can Fevarin cause weight gain or weight loss?

A: Official documentation lists both significant weight loss and unusual weight gain or loss as possible effects. For children and adolescents, monitoring of weight and growth is sometimes recommended in official guidelines.

Q: Can Fevarin affect a person's sleep patterns?

A: Official product information documents effects on sleep as commonly reported. These can include both insomnia (difficulty falling or staying asleep) and somnolence (drowsiness or feeling excessively sleepy). The recommended dosing schedule for this medication is generally designed to help manage potential sleep-related effects.

Q: Is it normal to feel a change in energy levels after starting Fevarin?

A: Yes, a change in energy can be experienced. Regulatory documents list asthenia as a common adverse reaction, which is a medical term for a lack of energy, weakness, or generalized debility. This is a recognized effect noted in the official safety profile.

Q: How long after stopping Fevarin do the effects typically wear off?

A: Fevarin is metabolized by the body over time. The multiple-dose elimination half-life—the time it takes for the concentration to reduce by half—is approximately 13 to 16 hours in adults. Most of the drug's components are excreted from the system within a few days, and the complete subsidence of effects is linked to the body's full clearance of the substance.

Q: Is Fevarin considered a long-term treatment?

A: Official guidance indicates that for patients who respond to treatment for chronic conditions like Obsessive-Compulsive Disorder (OCD), it is reasonable to consider continuation treatment. Patients should be periodically reassessed by their prescriber to determine the need for continued therapy.

Q: Does Fevarin affect the ability to drive or operate machinery?

A: Regulatory information cautions that the medication may cause drowsiness or affect a person's judgment, thinking, or motor skills. Official regulatory cautions advise against driving or operating complex machinery until a person knows how this medication affects their motor skills and alertness.

Q: What is the potential for withdrawal symptoms with Fevarin?

A: Official guidance advises a gradual dose reduction (tapering) rather than abrupt cessation. Symptoms associated with discontinuation have been reported and may include feelings of agitation, dizziness, confusion, or sensations described as 'electric shocks.' Official instructions describe the necessity of working with a professional for any dose adjustments or discontinuation.

Q: Do official documents mention specific concerns for people with liver or kidney issues when taking Fevarin?

A: Yes. For patients with hepatic impairment (liver issues), official instructions mandate a low starting dose and careful monitoring. Dose adjustments and monitoring are also advised for patients with renal impairment (kidney issues).

Q: Is a person's response to Fevarin affected by genetics?

A: The drug is processed, or metabolized, by liver enzymes called Cytochrome P450 (CYP) enzymes, whose activity can be influenced by genetic factors. This genetic variability can lead to individual differences in how the drug is processed in the body, potentially affecting its concentration.

Q: Can Fevarin cause changes in vision?

A: Official documentation notes that Fevarin may, in rare cases, cause or worsen a condition called angle-closure glaucoma, which affects the eyes and can lead to vision changes. Symptoms such as eye pain, sudden changes in vision, or seeing colored rings around lights are considered serious and require the attention of a healthcare provider.

Q: Do I need to have regular blood tests while taking Fevarin?

A: Official labeling highlights the risks of hyponatremia (low sodium levels in the blood) and an increased risk of bleeding when taken with certain other drugs. Although specific mandatory routine blood tests are not defined for all patients, monitoring for these risks may be required, and determining the necessity and frequency of blood monitoring is a decision made by the prescribing professional.

Q: Are generic versions of Fevarin available?

A: Yes, the medication is available under its generic name, Fluvoxamine maleate, as well as various brand names in many regulatory regions. Generic formulations have been approved by regulatory agencies.

Q: Can Fevarin be taken at any time of day?

A: The general recommended schedule for a single daily dose is to take it at bedtime. For larger daily doses that must be divided, regulatory documents state that the larger portion should still be given at bedtime to help manage potential side effects like drowsiness.

Q: What is the primary way Fevarin leaves the body?

A: Fevarin is extensively processed, or metabolized, by the liver into different components, which are generally inactive. These components are then primarily excreted from the body in the urine.

Q: Are there specific monitoring requirements for children taking Fevarin?

A: Yes, official labeling mandates close monitoring for the emergence of suicidal ideation and behavior, particularly in pediatric patients at the start of treatment or following dose changes. Additionally, regular monitoring of weight and growth is often recommended for children and adolescents taking the medication long-term.

Q: What is the generally accepted duration of treatment with Fevarin?

A: Studies examining the clinical benefit of Fevarin for Obsessive-Compulsive Disorder (OCD) typically observe outcomes over a period of 10 weeks. However, because OCD is considered a chronic condition, official guidance for patients who respond may include a recommendation for long-term continuation treatment.

Q: Can taking Fevarin affect dental or oral health?

A: Dry mouth (xerostomia) is documented as a common adverse reaction in the official safety profile. While the official documents do not directly discuss dental health, dry mouth is a recognized factor that may affect oral hygiene.

Q: Can Fevarin be used in combination with other similar medicines?

A: Co-administration with other serotonergic agents (including similar medicines like other SSRIs or SNRIs) carries a documented regulatory risk of Serotonin Syndrome. Official labeling documents this regulatory risk, indicating that such use is generally discouraged or requires professional management.

Q: Are there any official restrictions on who can prescribe Fevarin?

A: Fevarin is classified as a prescription-only medicine in many regulatory regions. This means it can only be obtained with a prescription written by a licensed healthcare provider who is authorized to prescribe such medications.

Q: Is Fevarin known to affect blood pressure?

A: Official labeling does not commonly list changes in blood pressure as a frequent effect. However, uncommon side effects have included orthostatic hypotension, which is a drop in blood pressure that can occur when standing up too quickly.

How should Fevarin be stored and disposed of?

The storage and disposal of Fevarin (fluvoxamine maleate) must strictly follow the conditions defined in official regulatory documents.

Required Storage Conditions

Fevarin must be stored at controlled room temperature, typically defined as between 15 C and 30 C (59 F and 86 F). The medication must be kept in the original container and maintained tightly closed to protect it from excess heat and moisture (e.g., not in the bathroom). It is mandated that the product be stored out of the sight and reach of children and away from freezing temperatures.

Official Disposal Instructions

Unused or expired Fevarin must not be disposed of in household waste or wastewater, a restriction intended to protect the environment. Patients must ask their pharmacist or healthcare professional for the correct method of discarding the medicine, which should align with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fevarin found in:

A-Z Index: